The Role of Clozapine in Treatment-Resistant Schizophrenia
There have been various definitions of treatment-resistant schizophrenia recommended by practice guidelines and various clinical trials. No clear consensus exists for a single definition, but in general treatment resistance has been defined as an inadequate response to at least two different antipsychotic trials at the maximally tolerated dose. Clozapine is recommended for those patients with clinically significant positive symptoms after failure of two or more trials of antipsychotic medications. In this chapter, we will be discussing the side effects associated with clozapine treatment and also the role of the other professionals.
KeywordsClozapine Agranulocytosis Myocarditis Urinary incontinence
“The authors have nothing to disclose”.
- 2.AA Pharma. Starting Patients on AA Clozapine. 2017.Google Scholar
- 7.Taylor D, Paton C, Shitij K. Prescribing guidelines in psychiatry: 12th edition. Wiley Blackwell: Oxford; 2015.Google Scholar
- 15.Fontana PG, Sumegi B. Association of Clozaril (clozapine) with cardiovascular toxicity. Novartis Pharmaceuticals Canada Inc. 2002.Google Scholar
- 23.AA Pharma. Using clozapine today: treating schizophrenia from tertiary care to community care. 2017;1(1).Google Scholar
- 24.Carrizo E, Fernandez V, Connell L, Sandia I, Prieto D, Mogollon J, Valbuena D, et al. Extended release metformin for metabolic control assistance during prolonged clozapine administration: a 14 week, double-blind, parallel group, placebo-controlled study. Schizophr Res. 2009;113(1):19–26.CrossRefPubMedGoogle Scholar
- 26.Freudenreich O, McEvoy J. Guidelines for prescribing clozapine in schizophrenia. UpToDate. Retrieved from: https://www.uptodate.com/contents/guidelines-for-prescribing-clozapine-in-schizophrenia.